Tags

Type your tag names separated by a space and hit enter

Effects of lycopene on the insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk.
Nutr Cancer. 2008; 60(3):342-53.NC

Abstract

Insulin-like growth factor-I (IGF-I) is an important growth factor associated with increased risk of premenopausal breast cancer. We conducted a randomized, placebo-controlled, double-blind, crossover trial to evaluate whether tomato-derived lycopene supplementation (30 mg/day for 2 mo) decreases serum levels of total IGF-I in premenopausal women with 1) a history of breast cancer (n=24) or 2) a high familial breast cancer risk (n=36). Also, IGF binding protein (IGFBP) increasing effects were evaluated. Lycopene supplementation did not significantly alter serum total IGF-I and other IGF system components in the 2 study populations combined. However, statistically significant discordant results were observed between the 2 study populations (i.e., P<0.05 for total IGF-I, free IGF-I, and IGFBP-3). Total IGF-I and IGFBP-3 were increased in the breast cancer survivor population [total IGF-I=7.0%, 95% confidence interval (CI)= -0.2 to 14.3%; IGFBP-3=3.3%, 95% CI=0.7-6.0%), and free IGF-I was decreased in the family history population (-7.6%, 95% CI= -14.6 to -0.6%). This randomized controlled trial shows that 2 mo of lycopene supplementation has no effect on serum total IGF-I in the overall study population. However, lycopene effects were discordant between the 2 study populations showing beneficial effects in high-risk healthy women but not in breast cancer survivors.

Authors+Show Affiliations

Division of Experimental Therapy and the Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18444168

Citation

Voskuil, Dorien W., et al. "Effects of Lycopene On the Insulin-like Growth Factor (IGF) System in Premenopausal Breast Cancer Survivors and Women at High Familial Breast Cancer Risk." Nutrition and Cancer, vol. 60, no. 3, 2008, pp. 342-53.
Voskuil DW, Vrieling A, Korse CM, et al. Effects of lycopene on the insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk. Nutr Cancer. 2008;60(3):342-53.
Voskuil, D. W., Vrieling, A., Korse, C. M., Beijnen, J. H., Bonfrer, J. M., van Doorn, J., Kaas, R., Oldenburg, H. S., Russell, N. S., Rutgers, E. J., Verhoef, S., van Leeuwen, F. E., van't Veer, L. J., & Rookus, M. A. (2008). Effects of lycopene on the insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk. Nutrition and Cancer, 60(3), 342-53. https://doi.org/10.1080/01635580701861777
Voskuil DW, et al. Effects of Lycopene On the Insulin-like Growth Factor (IGF) System in Premenopausal Breast Cancer Survivors and Women at High Familial Breast Cancer Risk. Nutr Cancer. 2008;60(3):342-53. PubMed PMID: 18444168.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of lycopene on the insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk. AU - Voskuil,Dorien W, AU - Vrieling,Alina, AU - Korse,Catharina M, AU - Beijnen,Jos H, AU - Bonfrer,Johannes M G, AU - van Doorn,Jaap, AU - Kaas,Reinie, AU - Oldenburg,Hester S A, AU - Russell,Nicola S, AU - Rutgers,Emiel J T, AU - Verhoef,Senno, AU - van Leeuwen,Flora E, AU - van't Veer,Laura J, AU - Rookus,Matti A, PY - 2008/4/30/pubmed PY - 2008/10/22/medline PY - 2008/4/30/entrez SP - 342 EP - 53 JF - Nutrition and cancer JO - Nutr Cancer VL - 60 IS - 3 N2 - Insulin-like growth factor-I (IGF-I) is an important growth factor associated with increased risk of premenopausal breast cancer. We conducted a randomized, placebo-controlled, double-blind, crossover trial to evaluate whether tomato-derived lycopene supplementation (30 mg/day for 2 mo) decreases serum levels of total IGF-I in premenopausal women with 1) a history of breast cancer (n=24) or 2) a high familial breast cancer risk (n=36). Also, IGF binding protein (IGFBP) increasing effects were evaluated. Lycopene supplementation did not significantly alter serum total IGF-I and other IGF system components in the 2 study populations combined. However, statistically significant discordant results were observed between the 2 study populations (i.e., P<0.05 for total IGF-I, free IGF-I, and IGFBP-3). Total IGF-I and IGFBP-3 were increased in the breast cancer survivor population [total IGF-I=7.0%, 95% confidence interval (CI)= -0.2 to 14.3%; IGFBP-3=3.3%, 95% CI=0.7-6.0%), and free IGF-I was decreased in the family history population (-7.6%, 95% CI= -14.6 to -0.6%). This randomized controlled trial shows that 2 mo of lycopene supplementation has no effect on serum total IGF-I in the overall study population. However, lycopene effects were discordant between the 2 study populations showing beneficial effects in high-risk healthy women but not in breast cancer survivors. SN - 0163-5581 UR - https://www.unboundmedicine.com/medline/citation/18444168/Effects_of_lycopene_on_the_insulin_like_growth_factor__IGF__system_in_premenopausal_breast_cancer_survivors_and_women_at_high_familial_breast_cancer_risk_ L2 - http://www.tandfonline.com/doi/full/10.1080/01635580701861777 DB - PRIME DP - Unbound Medicine ER -